Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | ACKR3 | P25106 | 3/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.52 |
| ▸ | APP | P05067 | 5/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | DRD5 | P21918 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.45 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6499869 | 0.91 | ACKR3 (0.58) | SIGMAR1ACKR3TMEM97APP | |
| SCHEMBL6499418 | 0.88 | APP (0.46) | ACKR3APP | |
| SCHEMBL6498560 | 0.85 | MEN1 (0.62) | SIGMAR1ACKR3TMEM97OPRM1OPRK1 | |
| SCHEMBL6500080 | 0.84 | CCR8 (0.50) | APP | |
| SCHEMBL6498806 | 0.83 | ACHE (0.50) | APP | |
| SCHEMBL6508928 | 0.83 | GAA (0.62) | APP | |
| SCHEMBL6500361 | 0.83 | APP (0.47) | APPDRD2 | |
| SCHEMBL6505243 | 0.83 | ACHE (0.51) | APP | |
| SCHEMBL6503409 | 0.82 | MCHR1 (0.47) | SIGMAR1APPDRD2DRD3 | |
| SCHEMBL6496812 | 0.82 | BCHE (0.55) | SIGMAR1TMEM97APPOPRM1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | SIGMAR1 525/4885ACKR3 17/4885TMEM97 1169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.